N. Kohli

发表

Biomimetic interfaces for a multifunctional biosensor array microsystem

A. Mason, J. Zeikus, R. Worden, 2004, Proceedings of IEEE Sensors, 2004..

Therapeutically Targeting ErbB3: A Key Node in Ligand-Induced Activation of the ErbB Receptor–PI3K Axis

V. Grantcharova, B. Schoeberl, U. Nielsen, 2009, Science Signaling.

MM-141, an IGF-IR– and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors

B. Schoeberl, U. Nielsen, J. Fitzgerald, 2013, Molecular Cancer Therapeutics.

Rapid optimization and prototyping for therapeutic antibody-like molecules

B. Schoeberl, U. Nielsen, J. Fitzgerald, 2013, mAbs.

Antitumor Activity of a Novel Bispecific Antibody That Targets the ErbB2/ErbB3 Oncogenic Unit and Inhibits Heregulin-Induced Activation of ErbB3

Ulrik B. Nielsen, Birgit Schoeberl, Bo Zhang, 2012, Molecular Cancer Therapeutics.

Sickle Cell Disease—Genetics, Pathophysiology, Clinical Presentation and Treatment

L. Hsu, K. Ominu-Evbota, B. Inusa, 2019, International journal of neonatal screening.

Novel HPLC-Based Screening Method to Assess Developability of Antibody-Like Molecules.

N. Kohli, Melissa L. Geddie, Neeraj Kohli, 2017, Methods in molecular biology.

Comprehensive optimization of a single-chain variable domain antibody fragment as a targeting ligand for a cytotoxic nanoparticle

U. Nielsen, A. Lugovskoy, Y. Jiao, 2015, mAbs.

Neuropathy Target Esterase Biosensor

R. Worden, Devesh Srivastava, I. Lee, 2010 .

Title: MM-141, an IGF-1R and ErbB3 directed bispecific antibody, overcomes network adaptations that limit activity of IGF-1R inhibitors

B. Schoeberl, U. Nielsen, J. Fitzgerald, 2013 .

Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy

Greg M. Thurber, J. Pinkas, Y. Setiady, 2020, Molecular Cancer Therapeutics.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

W. Kamoun, J. Marks, A. Lugovskoy, 2019, Nature Biomedical Engineering.

Development of disulfide-stabilized Fabs for targeting of antibody-directed nanotherapeutics

A. Lugovskoy, D. Drummond, D. Kirpotin, 2022, mAbs.

Improving the developability of an anti-EphA2 single-chain variable fragment for nanoparticle targeting

J. Marks, A. Lugovskoy, Y. Jiao, 2017, mAbs.

Nanostructured crosslinkable micropatterns by amphiphilic dendrimer stamping

R. Worden, I. Lee, N. Kohli, 2004 .

Nanostructured biosensor for measuring neuropathy target esterase activity.

Ilsoon Lee, R. Worden, Devesh Srivastava, 2007, Analytical chemistry.

A novel screening method to assess developability of antibody-like molecules

Melissa L Geddie, A. Lugovskoy, M. Razlog, 2015, mAbs.

Theoretical and experimental study of bi-enzyme electrodes with substrate recycling

R. Worden, I. Lee, R. Richardson, 2010 .

MM-131, a bispecific anti-Met/EpCAM mAb, inhibits HGF-dependent and HGF-independent Met signaling through concurrent binding to EpCAM

B. Schoeberl, U. Nielsen, A. Raue, 2019, Proceedings of the National Academy of Sciences.

Enhanced Targeting of the EGFR Network with MM-151, an Oligoclonal Anti-EGFR Antibody Therapeutic

U. Nielsen, J. Fitzgerald, O. Burenkova, 2015, Molecular Cancer Therapeutics.

Antibody-mediated targeting of TNFR2 activates CD8+ T cells in mice and promotes antitumor immunity

M. Muda, A. Raue, E. Tam, 2019, Science Translational Medicine.

Arrays of lipid bilayers and liposomes on patterned polyelectrolyte templates.

R. Worden, R. Ofoli, I. Lee, 2006, Journal of colloid and interface science.

Heteromeric tandem IgG4/IgG1 Fc

B. Schoeberl, U. Nielsen, A. Raue, 2019 .

Crystal structure of EpCAM in complex with scFv

B. Schoeberl, U. Nielsen, A. Raue, 2019 .

Crystal structure of Sema domain of the Met receptor in complex with FAB

B. Schoeberl, U. Nielsen, A. Raue, 2019 .

Challenging immunosuppression treatment in lung transplant recipients with kidney failure.

M. Carby, H. Lyster, A. Simon, 2016, Transplant Immunology.

Antitumour activity and tolerability of an EphA2-targeted nanotherapeutic in multiple mouse models

W. Kamoun, J. Marks, A. Lugovskoy, 2019, Nature Biomedical Engineering.

Optimizing properties of antireceptor antibodies using kinetic computational models and experiments.

B. Schoeberl, U. Nielsen, B. Harms, 2012, Methods in enzymology.

Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity

B. Schoeberl, U. Nielsen, J. Fitzgerald, 2012 .